fda glp-1 compounding crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA GLP-1 Compounding Crackdown

Compared to the placebo (-4.0), liraglutide resulted in a greater change in BMI as a percentage of the 95th percentile (-14.0), and an estimated treatment difference of 10.0 (95% CI, 15.1 to 4.8) was observed

Caught early on, lifestyle changes could reduce your risk

(1998) found that in cultured lamb adenohypophysial cells, the combination of 10 nM GHRH plus 1 M GHRP-6 was not significantly different from GHRH alone

More than 80% of these occurrences manifest as non-arteritic anterior ischemic optic neuropathy (NAION)

The two manufacturers of approved GLP-1s, Lilly and Novo Nordisk, have set up online platforms to bypass both compounding and traditional pharmacies, and Lilly has partnered with three telehealth services to provide access to obesity-trained doctors and registered dietitians